Title : RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.

Pub. Date : 2018 Feb 8

PMID : 29059158






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 In this study, we found that combinatory treatment with LY3009120 and abemaciclib synergistically inhibited proliferation of tumor cells in vitro and led to tumor growth regression in xenograft models with a KRAS, NRAS or BRAF mutation at the doses of two drugs that were well tolerated in combination. LY3009120 NRAS proto-oncogene, GTPase Homo sapiens